Clinical trials: Upper Limb
OME - Otitis Media With Effusion, AOM - Acute Otitis Media
In-Office Tympanostomy Tube Placement in Children (OTTER)
A prospective, single-arm, multicenter study to evaluate effectiveness and safety of Tymbion iontophoresis and tympanostomy tube placement using the Tula Iontophoresis and Tube Delivery Systems for children in an office setting.
- Trial name
- OTTER (NCT03323736)
- Testing
- Iontophoresis & tube placement, Tube placement
- Where
- 19 sites in United States, Canada
- Volunteers
- 370 people
- Sponsor
- Tusker Medical
Neoplasms, Cancer of the Ovary
Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
This study evaluated outcomes in participants with advanced ovarian epithelial adenocarcinoma receiving aflibercept. The primary objective was to compare the objective response rate of Aflibercept (ziv-aflibercept, AVE0005, VEGF…
- Trial name
- NCT00327171
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 11 sites in United States, Australia and 9 more
- Volunteers
- 218 people
- Sponsor
- Sanofi
HIV Positive, Alcohol Use
Alcohol Research Consortium in HIV-Intervention Research Arm
Aim 1: Examine effects of algorithm-guided alcohol treatment on alcohol consumption and alcohol use Disorders (AUD) symptoms. Aim 2: Examine effects of algorithm-guided alcohol treatment on retention in HIV care and HIV-related…
- Trial name
- ARCH-IRA (NCT02938377)
- Testing
- Computerized Brief Intervention (CBI), CBT4CBT, Recommendation and Counseling for Alcohol Pharmacotherapy
- Where
- 2 sites in United States
- Volunteers
- 4,985 people
- Sponsor
- University of Alabama at Birmingham
Follicular Lymphoma
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
This study focuses on finding a safe and tolerable dose for a three-drug regimen that combines venetoclax (Venclexta Ⓡ), CC-486 (also known as oral azacitidine) and obinutuzumab (Gazyva Ⓡ) to treat cancer participants who have…
- Trial name
- NCT04722601
- Testing
- Venetoclax, Obinutuzumab, CC-486
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Thrombotic Microangiopathy
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA.
- Trial name
- NCT04557735
- Testing
- Ravulizumab, Best Supportive Care
- Where
- 26 sites in United States, Israel and 5 more
- Volunteers
- 41 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Osteoarthritis
Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee
An open-label, single-arm clinical trial to confirm the safety of monoarticular injections or bi-lateral intra-articular injections of RTX-GRT7039 in patients who have pain associated with osteoarthritis of the knee despite…
- Trial name
- NCT05377489
- Testing
- RTX-GRT7039
- Where
- 96 sites in United States, Bulgaria and 5 more
- Volunteers
- 714 people
- Sponsor
- Grünenthal GmbH
Lymphoma, Mantle- Cell
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
This study was to evaluate the safety and efficacy of a daily, oral dose of 10 mg RAD001 in participants with Mantle Cell Lymphoma who were refractory or intolerant to Velcade® therapy and who had received at least one prior…
- Trial name
- PILLAR-1 (NCT00702052)
- Testing
- Everolimus
- Where
- 31 sites in United States
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Atypical Meningioma, Anaplastic Meningioma
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
- Conditions
- Atypical Meningioma, Anaplastic Meningioma, Hemangiopericytoma
- Trial name
- NCT03016091
- Testing
- Pembrolizumab
- Where
- 2 sites in Israel
- Volunteers
- 18 people
- Sponsor
- Rabin Medical Center
Lower Limb Amputation Above Knee (Injury)
C-Leg 3 and C-Leg 4 Study in Transfemoral Amputees
The aim of this post-market study is to confirm that the microprocessor controlled prosthetic knee components (C-Leg 3 and C-Leg 4) in comparison to mechanical knee joints can bring additional benefit to the users primarily on…
- Trial name
- NCT02765035
- Testing
- C-Leg 4, C-Leg 3
- Where
- 2 sites in Austria, Belgium
- Volunteers
- 18 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Multiple Sclerosis
MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
This is a prospective, multicenter, open label, uncontrolled, non-interventional, single arm study to measure treatment satisfaction of relapsing remitting MS (RRMS) participants on Rebif after discontinuing initial first-line…
- Trial name
- MESTRE-MS (NCT02949908)
- Testing
- Rebif
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lateral Epicondylitis
Treatment of Tendon Injury Using Mesenchymal Stem Cells
Main purpose of this study is to evaluate efficacy and safety of allogenic adipose-derived mesenchymal stem cells(ALLO-ASC) in treatment of tendon injury.
- Trial name
- ALLO-ASC (NCT01856140)
- Testing
- ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Psoriasis
Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis
This is a phase I, open label, single group study that is being performed to assess the safety, tolerability, Pharmacokinetics (PK) , Pharmacogenomics (PGx) and efficacy of a single dose of spesolimab in adult patients with…
- Trial name
- NCT02978690
- Testing
- Spesolimab
- Where
- 6 sites in France, Japan and 4 more
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Low Back Pain
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administrated tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate…
- Trial name
- NCT00449176
- Testing
- tapentadol (CG5503) ER, oxycodone CR
- Volunteers
- 981 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection
The main objective of this trial is to compare the pharmacokinetics (PK) of 40 mg BI 695501 100 mg/mL with 40 mg BI 695501 50 mg/mL following single subcutaneous administration.
- Trial name
- NCT05203289
- Testing
- BI 695501 - higher concentration, BI 695501 - lower concentration
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Bladder Cancer
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy.
- Trial name
- CIRTiN-BC (NCT04779489)
- Testing
- personalized ultrafractionated stereotactic ablative radiotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
This study will be conducted to evaluate the safety, pharmacokinetics (PK), and efficacy of adjunctive GWP42003-P in participants < 2 years of age with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), or Dravet…
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Trial name
- NCT04485104
- Testing
- GWP42003-P
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Diffuse Large B-cell Lymphoma (DLBCL)
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
- Trial name
- JULIET (NCT02445248)
- Testing
- Tisagenlecleucel, Lymphodepleting chemotherapy
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
BRAF V600E-mutant Metastatic Colorectal Cancer
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received…
- Trial name
- ANCHOR-CRC (NCT03693170)
- Testing
- encorafenib, Binimetinib, Cetuximab
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 95 people
- Sponsor
- Pierre Fabre Medicament
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
This study is designed to assess the safety and efficacy of palonesetron in preventing chemotherapy-induced nausea and vomiting (CINV) when administered to participants who have experienced either vomiting and or at least…
- Trial name
- NCT01054456
- Testing
- palonesetron
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Eisai Inc.
Moderate to Severe Rheumatoid Arthritis
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
- Trial name
- ROCkIES (NCT01927757)
- Testing
- Etanercept, Methotrexate
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 90 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.